Phase 3 data on sunvozertinib for EGFR exon 20 insertions and sacituzumab tirumotecan plus pembrolizumab for PD-L1-positive ...
For patients with non–small cell lung cancer (NSCLC) that has tested positive for EGFR mutations, treatment with targeted EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib (Tarceva, Osi ...
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, today announced the presentations of two studies in ...
Non-small cell lung cancer is increasingly evolving into a biomarker-driven market, with EGFR-mutated disease emerging as one ...
First-line sunvozertinib treatment significantly prolongs progression-free survival vs chemotherapy in advanced NSCLC with ...
NSCLC is the most frequent histological subtype of lung cancer, accounting for approximately 85% of patients with lung cancer. NSCLC includes a variety of different lung cancers, most notably ...
GA, UNITED STATES, February 15, 2026 /EINPresswire.com/ — A groundbreaking phase 2 clinical trial has unveiled promising advancements in the treatment landscape for ...
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
Zegfrovy (sunvozertinib) received accelerated FDA approval for NSCLC patients with EGFR exon 20 insertion mutations post-platinum-based chemotherapy progression. The Oncomine Dx Express Test was ...
The EGFR-NSCLC pipeline possesses some drugs in late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results